Santarus

About Santarus

Santarus, Inc. operated as a specialty biopharmaceutical firm, concentrating on the acquisition, development, and commercialization of products aimed at patients under the care of specialist physicians. The company was established in December 1996 in California and later reincorporated in Delaware in July 2002. One of its founders was Gerald T. Proehl, who also served as President and CEO from 2002 until 2014. His career includes a 14-year tenure at Hoechst Marion Roussel, where he held several roles, including Vice President of Global Marketing, gaining experience in therapeutic areas like cardiology and immunology. Another key figure was Wendell Wierenga, who served as Executive Vice President of Research and Development from 2011 to 2014 and brought decades of experience from roles at companies like Upjohn Pharmaceuticals, Parke-Davis/Warner Lambert, and Neurocrine Biosciences.

The company's business model was centered on identifying, developing, and bringing to market pharmaceutical products, particularly for gastrointestinal (GI) diseases and disorders. Santarus focused on next-generation proton pump inhibitors (PPIs), which are widely prescribed for upper GI conditions. Its revenue was generated through the sale of its portfolio of pharmaceutical products. The company's strategy also involved out-licensing products to partners in specific markets. A significant milestone for Santarus was its acquisition by Salix Pharmaceuticals in a transaction valued at approximately $2.6 billion, which was announced in November 2013 and completed in the first quarter of 2014. This acquisition was a strategic move by Salix to solidify its position in the gastroenterology market and diversify its product offerings.

Santarus's product portfolio included several key commercial drugs. UCERIS® (budesonide) was an extended-release tablet for treating mild to moderate ulcerative colitis, and ZEGERID® (omeprazole/sodium bicarbonate) was used for certain upper gastrointestinal disorders; both were promoted to gastroenterologists. The company also diversified beyond GI treatments with products like GLUMETZA® and CYCLOSET® for Type 2 diabetes, and FENOGLIDE® for lowering high cholesterol. Prior to its acquisition, Santarus's development pipeline included RUCONEST®, an investigational drug for hereditary angioedema, and rifamycin SV MMX® for traveler's diarrhea. The company built its product candidates by leveraging Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act, which allows for regulatory submissions to include data from studies not conducted by the applicant.